FDA Does Not Approve TKI Surufatinib for Neuroendocrine Tumors FDA Does Not Approve TKI Surufatinib for Neuroendocrine Tumors

Drug manufacturer Hutchmed said the FDA sent the company a complete response letter indicating that the agency requires a multiregional clinical trial before approving the drug in the US.News Alerts
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news